Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2014

View Archived Issues

A functional serotonin receptor polymorphism as a biomarker for cardiovascular disease

GlycoMimetics presents data from phase II trial of GMI-1070 in sickle cell disease

Stress-related transcription factor promotes fibrosis and oncogenesis

Application of site-directed RNA editing to correct disease-causing genetic mutations

Development of a novel ROR1 peptide-based cancer vaccine

Astellas Pharma and ClearPath Development to build vaccine company portfolio

Emmaus Medical completes all patient visits in phase III sickle cell disease trial

Trovagene and US Oncology Research collaborate on urine-based KRAS testing study

ERYtech plans phase II study of ERY-ASP in pancreatic cancer

DURECT grants Impax worldwide rights to develop and commercialize ELADUR pain patch

Amunix and Janssen extend worldwide collaboration and licensing agreement

Galena enrolls first patient in phase II trial of GALE-301 cancer immunotherapy in ovarian cancer

Immunovative Therapies updates Allovax plans

Takeda's vedolizumab enters phase III trials in Japan for ulcerative colitis and Crohn's disease

Adocia initiates phase IIa trial of ultra-fast acting formulation of insulin lispro

FDA accepts NPS Pharmaceuticals' BLA for Natpara for hypoparathyroidism

Reata reports discovery of epoxidized triterpenoids

Austrian group patents novel agents for protozoal infections

Ribomic presents new aptamers for rheumatoid arthritis and other disorders

Novel LPA-1 receptor antagonists presented by Roche

Roche divulges novel FABP inhibitors

FDA approves phase IIb study of PRO-140 for HIV-1

TeaRx begins phase II trial of novel anticoagulant in Russia

Catalyst Pharmaceutical reports cardiac safety results from phase III Firdapse trial

Forest Laboratories enters definitive agreement to acquire Aptalis

Bristol-Myers Squibb and AstraZeneca gain FDA approval for Forxiga in type 2 diabetes

Daiichi Sankyo files applications for oral, once-daily anticoagulant edoxaban in Europe and U.S.

GSK obtains accelerated FDA approval for use of Mekinist in combination with Tafinlar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...